Volume 28, Number 9—September 2022
Research
Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006–2019
Table 3
Characteristic | Total, N = 298 | TB resistance status | p value |
*Values are no (%) except as indicated. IQR, interquartile range; MDR, multidrug resistant (susceptible to all fluoroquinolones); NS, not statistically significant; pre-XDR/XDR = pre–extensively drug resistant/extensively drug resistant, (resistant to >1 fluoroquinolone); TB, tuberculosis. †Among patients with treatment success at end of treatment. ‡These patients did not attend follow-up appointments and did not respond to attempted contact from clinical staff. §Among patients with a positive sputum culture at treatment start.
Page created: July 31, 2022
Page updated: August 19, 2022
Page reviewed: August 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.